BridgeBio Oncology: chief med & dev officer Ben Yong sold 1,047 shares

What happened Ben Yong, chief med & dev officer, had 1,047 shares withheld by the issuer to satisfy tax withholding in connection with the vesting of restricted stock units. The filing reports a per-share price of $3.94 and a total value of $4,125. The transaction date is Oct 1, 2026 and the Form 4 was filed on Oct 5, 2026.

Key details

• Transaction date and price: Oct 1, 2026; $3.94 per share.
• Shares withheld/disposed: 1,047; total value $4,125.
• Shares owned after the transaction: not stated in the provided filing details.
• Footnote F1: represents the number of shares withheld by the issuer to satisfy the reporting person’s tax withholding obligations in connection with the vesting of restricted stock units.
• Filing date: Oct 5, 2026; the filing does not include a lateness indicator.

Why it may matter

• The transaction code is F, indicating issuer withholding of shares to cover tax obligations tied to RSU vesting; the shares were withheld by the issuer rather than sold on the open market.
• A filing does not show why the insider traded or why the company acted.